Back to Top Skip to main content Skip to sub-navigation

Defending the Homeland: Turning on lifesaving trials at Madigan Army Medical Center

Image of soldier in front of a laptop Janell Cain, a clinical research coordinator at Madigan with the Infectious Disease Clinical Research Program, records the informed consent forms signed by a patient receiving treatment for COVID-19 in the intensive care unit from Madigan’s Virtual Critical Care Center on April 14. Communicating with the patient and nurses via the video equipment, Cain gains the necessary consent to enroll a patient in a study of remdesivir as a COVID-19 treatment without expending personal protective equipment, or exposing anyone to the patient unnecessarily. The IDCRP is a Department of Defense-wide research consortium headquartered at the Uniformed Services University for the Health Sciences in Bethesda, Md. (Lt. Col. (Dr.) Christopher Colombo)

Recommended Content:

Coronavirus

MADIGAN ARMY MEDICAL CENTER, Joint Base Lewis-McChord, Wash. – Madigan Army Medical Center, on Joint Base Lewis-McChord, Wash., has been a hotbed for biomedical research for years, highlighted by patented innovations and award winning presentations at national and international scientific meetings.

In response to the COVID-19 global pandemic, Madigan is currently supporting nine research protocols designed to address gaps in knowledge including clinical characteristics of the COVID-19 illness, the impact of nutrition on COVID-19 risk, and the clinical value of convalescent plasma, in which a patient with severe disease is given plasma from someone who has recovered from COVID-19 and therefore has antibodies to it in their blood, to name a few.

Possibly the most notable clinical trial for COVID-19 treatment involves remdesivir, an investigational, broad-spectrum antiviral drug that has shown some promise, in animal trials, in both Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), which are caused by other coronaviruses.

The trial is sponsored by the National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health, and is the first clinical trial in the U.S. to evaluate an experimental treatment for COVID-19.

When the trial began in February, Dr. Anthony Fauci, the director of NIAID and a member of the U.S. Coronavirus Task Force said, “We urgently need a safe and effective treatment for COVID-19. Although remdesivir has been administered to some patients with COVID-19, we do not have solid data to indicate it can improve clinical outcomes. A randomized, placebo-controlled trial is the gold standard for determining if an experimental treatment can benefit patients.”

Madigan is one of 68 international trial sites among 47 in the U.S. and 21 in Europe and Asia. The first enrollee was at the University of Nebraska Medical Center/Nebraska Medicine, in February; he had been on a cruise ship that saw a number of infections.

The initiation of the trial can is described here: https://www.niaid.nih.gov/news-events/nih-clinical-trial-remdesivir-treat-covid-19-begins.

Within two months of initiation, the clinical trial of remdesivir has produced encouraging results.

In a statement issued on April 29, the NIAID reported, “Preliminary results indicate that patients who received remdesivir had a 31 percent faster time to recovery than those who received placebo (p<0.001). Specifically, the median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo. Results also suggested a survival benefit, with a mortality rate of 8.0 percent for the group receiving remdesivir versus 11.6 percent for the placebo group (p=0.059).”

This trial is managed at Madigan by the Infectious Disease Clinical Research Program, a Department of Defense-wide research consortium headquartered at the Uniformed Services University for the Health Sciences in Bethesda, Md. The IDCRP conducts clinical research that focuses on reducing the impact of infectious diseases relevant to the DoD.

For more information about the IDCRP, visit: https://www.idcrp.org/about-us.

The IDCRP has a broad research portfolio, including an ongoing study looking at the efficacy of different formulations of the flu vaccine. When COVID-19 emerged, the IDCRP pivoted to get this research up and running in a very short period of time. As an established IDCRP site, Madigan was identified as one of the military treatment facilities eligible for participation in the NIAID trial.

“Because they are so active and such a squared-away group, they were able to help get this trial off the ground,” said Lt. Col. (Dr.) Christopher Colombo, principal investigator for the COVID-19 trial and the director of Virtual Health and Telecritical Care at Madigan.

Madigan has strong and adaptive biomedical research capabilities that are facilitated by its Department of Clinical Investigation.

“The Department of Clinical Investigation, Dr. Rick Burney (DCI’s chief) and Dr. (Silvija) Salai (the human subject protection administrator), have been fantastic in supporting and expediting this and balancing making sure that everything is still done dress-right-dress according to regulatory, safety and scientific integrity filings, but it is going quite a bit faster than usual, because of the situation that we're in,” noted Lt. Col. Colombo.

Madigan is one of five DoD sites that has enrolled patients in the study so far and is already ramping up for its next phase. Investigators stress that these are early days of evaluation for this trial. Given the high transmissibility and global spread of this virus, research has moved quickly.

“It's a placebo controlled trial, so the patients are randomized. We don't know who's getting what. They either get placebo or remdesivir,” Lt. Col. Colombo said.

NIH requirements for inclusion in the trial comprise the need for hospitalization for documented COVID-19 infection and either an abnormal chest x-ray or the requirement for supplemental oxygen or mechanical ventilation. Trial participation is limited to adults.

Participants in the treatment group get 200 milligrams (mg) of remdesivir injected on the first day they are in the study and 100 mg each day of their hospitalization, up to 10 days total. Those in the placebo group receive the same amount of what looks like remdesivir but contains only inactive ingredients.

This means the trial is administered to patients currently being treated in the hospital, though some have since improved and gone home. They return to the hospital periodically for monitoring.

Dr. Rhonda Colombo, an infectious diseases physician who works in support of the IDCRP at Madigan, praised the contributions of patients who volunteered to participate in this and other ongoing clinical research trials.

“Without willing and engaged study participants, clinical research is not possible. At Madigan, we are incredibly fortunate to be part of a community that values clinical research. Our research team is humbled by the generosity and commitment of the people who volunteer to participate in our studies,” said Dr. Colombo.

With drug safety and long-term effects always in mind, the team is not yet ready to draw conclusions, but is optimistic about the data so far.

Susan Chambers, the clinical operations manager for the IDCRP at Madigan echoed that appreciation for the high value that Madigan, and the JBLM community place on research, noting that it is the providers and nurses on the inpatient units who directly support research within their care of patients.

“We are incredibly proud to have the opportunity to offer access to cutting-edge research for our Active Duty personnel and DoD beneficiaries. Our success would not be possible without the support of Madigan Commander Col. Thomas Bundt and the committed inpatient clinical care teams at Madigan,” said Chambers.

On Friday, May 1, the U.S. Food and Drug Administration gave remdesivir emergency use authorization to treat COVID-19.

The NIAID expects to share additional data soon, as well as next steps.

“We managed to get meaningful research turned on, very quickly. Other sites in the Department of Defense, are kind of looking at Madigan like you guys are knocking it out of the park, keep going,” said Lt. Col. Colombo. “I think it's something that's cool in terms of how we're responding to COVID in a positive way and making some good come of this.”

Disclaimer: Re-published content may be edited for length and clarity.  Read original post.

You also may be interested in...

Q & A: Policy Exception for Telehealth Use for ABA during COVID-19 Pandemic

Publication
3/30/2020

Question and Answer: TRICARE Autism Care Demonstration (ACD): Regarding Temporary Authorization to Utilize Telehealth for CPT Code 97156 during the COVID-19 National Emergency

Recommended Content:

Coronavirus | TRICARE Health Program

Policy Exception for Telehealth Use for ABA during COVID-19 Pandemic

Publication
3/30/2020

Communication to ABA Providers Regarding Temporary Authorization to Utilize Telehealth for CPT Code 97156 During the COVID-19 National Emergency

Recommended Content:

Coronavirus | TRICARE Health Program

Military scientists, engineers develop ventilator prototype in response to COVID-19

Article
3/27/2020
Dr. Andrew Schicho, Naval Surface Warfare Center, Panama City Division mechanical engineer, led one of the five teams by building a ventilator prototype in support of the Department of Defense Hack-a-Vent Innovation Challenge. (U.S. Navy photo by Eddie Green)

The team decided that building ventilators was how they serve the best at a time like this.

Recommended Content:

Coronavirus

200 new doctors, nurses to join military medical ranks early

Article
3/27/2020
Military medical professionals take their oath at their graduation from the Uniformed Services University of the Health Sciences during a ceremony in Washington, May 18, 2019. More than 200 USU military medical students and graduate nursing students will be graduating early in 2020 to support their colleagues in the U.S. military health system amid the global coronavirus pandemic. (DoD file photo)

Military medical students will be graduating early to support the Military Health System amid the coronavirus pandemic

Recommended Content:

Coronavirus | Nurses Week

In a COVID-19 world, pace yourself to stay resilient and avoid burnout

Article
3/26/2020
Kelly Blasko, Ph.D., is a clinical psychologist and the lead for mobile health clinical integration at the Defense Health Agency Connected Health branch. She shares what providers can do to pace themselves and use self-care practices and tools to stay resilient and avoid burnout. (DoD photo by Savannah Blackstock)

Our response to COVID-19 is a marathon, not a sprint

Recommended Content:

Coronavirus | Coronavirus

Need for blood donations constant despite COVID-19

Article
3/26/2020
Medical soldiers from the 230th Brigade Support Battalion, 30th Armored Brigade Combat Team, North Carolina National Guard, host a blood drive at Fort Bliss, Texas. The need for donated blood is especially critical during the COVID-19 pandemic. (U.S. Army photo by Lt. Col. Cindi King)

Limited shelf life, canceled blood drives threaten supply

Recommended Content:

Coronavirus | Coronavirus

Nearly 10,000 Guardsmen called up for COVID-19 response

Article
3/25/2020
Army Sgt. Moises Castillo of the California Army National Guard helps an Amador County resident load food supplies into a vehicle at the Interfaith Food Bank in Jackson, Calif., March 23, 2020. (U.S. Army photo illustration by Army National Guard Staff Sgt. Eddie Siguenza)

The president left control of the National Guard to the governors and the adjutant generals

Recommended Content:

Combat Support | Public Health | Coronavirus | Coronavirus

USNS Mercy departs San Diego

Article
3/24/2020
The hospital ship USNS Mercy navigates the San Diego channel March 23. Mercy deployed in support of the nation’s COVID-19 response efforts, and will serve as a referral hospital for non-COVID-19 patients currently admitted to shore-based hospitals. This allows shore base hospitals to focus their efforts on COVID-19 cases. One of the Department of Defense’s missions is Defense Support of Civil Authorities. DoD is supporting the Federal Emergency Management Agency, the lead federal agency, as well as state, local and public health authorities in helping protect the health and safety of the American people. (U.S. Navy photo by Mass Communication Specialist 3rd Class Lasheba James)

Mercy's mission is to provide full hospital services to support U.S. disaster relief and humanitarian operations worldwide.

Recommended Content:

Civil Military Medicine | Civil Support | Public Health | Coronavirus | Coronavirus

DoD aims to fill medical gaps with military while states, cities ramp up

Article
3/24/2020
Defense Secretary Dr. Mark T. Esper speaks to reporters during a news conference at the Pentagon to discuss the department's efforts in response to the COVID-19 pandemic, March 23, 2020. (DoD photo by Army Staff Sgt. Brandy Nicole Mejia)

The secretary sees the military filling gaps in cities, states until they can deal with COVID-19 on their own

Recommended Content:

Combat Support | Public Health | Coronavirus | Coronavirus

A full night’s sleep could be the best defense against COVID-19

Article
3/23/2020
Sleep is critical for maintaining physical, cognitive and immunological dominance on and off the battlefield. Leaders must prioritize sleep as a valuable asset in maintaining readiness and resilience, especially in the context of multi-domain operations and increased health risks worldwide – including those risks associated with exposure to infectious diseases (U.S. Army photo by Robert Timmons)

Getting more sleep could dramatically improve your odds of avoiding infection

Recommended Content:

Combat Support | Public Health | Coronavirus | Coronavirus | Total Force Fitness

Air Force takes steps to assure ‘unblinking’ operations, readiness and capabilities amid pandemic

Article
3/23/2020
Air Force medics and health personnel around the globe are resolutely following and ensuring compliance with guidelines issued by the Department of Defense and Centers for Disease Control and Prevention according to Air Force Lt. Gen. Dorothy Hogg.

Within the Air Force, our medics are executing all available measures to mitigate the spread of COVID-19

Recommended Content:

Combat Support | Public Health | Coronavirus | Coronavirus

Addressing emotional responses to threat of Coronavirus

Article
3/20/2020
U.S. Air Force Master Sgt. Kathleen A. Myhre, 446th Airman and Family Readiness Center noncommissioned officer in charge, meditates outside the 446th Airlift Wing Headquarters building on Joint Base Lewis-McChord, Washington, Feb. 12, 2020. Myhre traveled to India in 2016 to study to become an internationally-certified yoga instructor. She now shares her holistic training with Reserve Citizen Airmen of the 446th AW. (U.S. Air Force photo by Staff Sgt. Mary A. Andom)

Even if you’re feeling healthy, medical professionals recommend staying home and limiting social contact as much as possible

Recommended Content:

Medical and Dental Preventive Care Fitness | Psychological Fitness | Physical Fitness | Combat Support | Public Health | Coronavirus | Coronavirus

Place addresses DHA COVID-19 response

Article
3/19/2020
Lt. Gen. Ronald Place, director of the Defense Health Agency, and Rear Adm. Bruce Gillingham, surgeon general of the Navy, discuss plans for additional COVID-19 response efforts with the Pentagon Press Corps.

Crisis Action Team part of broad-based effort

Recommended Content:

Combat Support | Public Health | Coronavirus | Coronavirus

COVID-19 Life Support Training Extension

Publication
3/19/2020

The purpose of this memorandum is to set policy guidance within the Military Health System for American Red Cross life support training (First Aid/cardiopulmonary resuscitation (CPR)/automated external defibrillator (AED), Basic Life Support (BLS), Advanced Life Support (ALS), and Pediatric Advanced Life Support (PALS)).

Recommended Content:

Coronavirus

DoD ready to help with Coronavirus, but capability limited

Article
3/17/2020
Misook Choe, a laboratory manager with the Emerging Infectious Disease branch at the Walter Reed Army Institute of Research in Silver Spring, Md., runs a test during research into a solution for the new coronavirus, COVID-19, March 3, 2020. The Emerging Infectious Diseases branch, established in 2018, has the explicit mission to survey, anticipate and counter the mounting threat of emerging infectious diseases of key importance to U.S. forces in the homeland and abroad. (U.S. Army Sgt. Michael Walters)

The DoD has only about 2% to 3% of the number of hospital beds that the private sector has

Recommended Content:

Combat Support | Public Health | Coronavirus | Coronavirus
<< < ... 31 32 33 > >> 
Showing results 466 - 480 Page 32 of 33

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.